Thursday, July 13, 2023
Velico Medical has initiated a Phase I safety study to assess the efficacy and safety of their innovative product called FrontlineODP (OnDemandPlasma) Spray Dried Plasma. This clinical trial, involving dose escalation, is being conducted at multiple centers including Hoxworth Blood Center in Cincinnati, Ohio, Versiti Blood Center of Wisconsin in Milwaukee, Wisconsin, and Spaulding Clinical Research in West Bend, Wisconsin. Notably, this trial marks the first time Velico's spray drying system is being utilized in human subjects.
Richard Meehan, President and CEO of Velico, expressed the importance of their clinical trial, stating, "Plasma plays a critical role in preventing trauma-induced coagulopathy. The quest for dried plasma has been ongoing for over two decades, and this trial represents a significant milestone in our mission to provide a life-saving product for the medical and emergency response community."
Dr. Mark Popovsky, Chief Medical Officer at Velico, highlighted the need for a plasma product that can be administered prior to a patient's arrival at a trauma center, saying, "Clinicians treating life-threatening hemorrhage require a plasma product that can be given quickly. Spray-dried plasma combines the biological effectiveness of frozen plasma with logistical convenience, which is vital in time-sensitive situations where minutes can make a difference between life and death."
Dr. José Cancelas, Director of the Hoxworth Blood Center at the University of Cincinnati College of Medicine, emphasized the role of dried plasma in transfusion care for bleeding patients. He stated, "Dried plasma will become an integral part of transfusion care for patients experiencing bleeding. In prehospital and emergency care settings, where time is critical, dried plasma plays a crucial role."
Velico's development program has received funding, in whole or in part, from the Department of Health and Human Services through the Administration for Strategic Preparedness and Response and the Biomedical Advanced Research and Development Authority. The contract number associated with the funding is 75A50121C00059.